At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADC Agree
Not Yet Opened 01-09 16:00:00 EST
70.51
-0.30
-0.42%
盘后70.51
+0.000.00%
19:43 EST
High71.12Low69.56Vol1.71M
Open70.56D1 Closing70.81Amplitude2.20%
Mkt Cap8.10BTradable Cap7.64BTotal Shares114.93M
T/O119.99MT/O Rate1.57%Tradable Shares108.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
TIPRANKS  ·  07:32
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
Zymeworks Outlines Strategic Priorities and Outlook for 2026
GlobeNewswire  ·  07:00
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
GlobeNewswire  ·  06:00
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up
Simply Wall St.  ·  01-10 01:19
Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up
Beyond the Title: The Significance Behind the Recognition
Deep News  ·  01-09
Beyond the Title: The Significance Behind the Recognition
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
TIPRANKS  ·  01-09
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
ADC Therapeutics sees FY25 net product revenue $73M
TIPRANKS  ·  01-09
ADC Therapeutics sees FY25 net product revenue $73M
ADC Therapeutics sees Q4 net product revenue $22M
TIPRANKS  ·  01-09
ADC Therapeutics sees Q4 net product revenue $22M
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
GlobeNewswire  ·  01-08
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
UBS Keeps Their Buy Rating on Agree Realty (ADC)
TIPRANKS  ·  01-08
UBS Keeps Their Buy Rating on Agree Realty (ADC)
Chengdu Hosts Nearly 70% of Sichuan's Corporate Headquarters: The Story Behind the Numbers
Deep News  ·  01-08
Chengdu Hosts Nearly 70% of Sichuan's Corporate Headquarters: The Story Behind the Numbers
HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma
Stock News  ·  01-08
HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma
Top News Today/Canada: Air Transat, Pilots Agree to Deal
Dow Jones  ·  01-07
Top News Today/Canada: Air Transat, Pilots Agree to Deal
Agree Realty Corporation Schedules Earnings Release and Conference Call
Reuters  ·  01-07
Agree Realty Corporation Schedules Earnings Release and Conference Call
Agree Realty Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Information
THOMSON REUTERS  ·  01-07
Agree Realty Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Information
U.K. and France Agree to Set Up Military Hubs Across Ukraine After Ceasefire -- WSJ
Dow Jones  ·  01-07
U.K. and France Agree to Set Up Military Hubs Across Ukraine After Ceasefire -- WSJ
Agree Realty Is Maintained at Outperform by RBC Capital
Dow Jones  ·  01-07
Agree Realty Is Maintained at Outperform by RBC Capital
Day One Completes Acquisition of Mersana Therapeutics
GlobeNewswire  ·  01-06
Day One Completes Acquisition of Mersana Therapeutics
RBC Lowers Price Target on Agree Realty to $79 From $80, Keeps Outperform Rating
MT Newswires Live  ·  01-06
RBC Lowers Price Target on Agree Realty to $79 From $80, Keeps Outperform Rating
BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program
Stock News  ·  01-06
BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program

Introduction

Company Name.
Agree
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Agree Realty Corporation (the “Company”), a Maryland corporation, is a fully integrated real estate investment trust (“REIT”) primarily focused on the ownership, acquisition, development and management of retail properties net leased to industry leading tenants. The Company was founded in 1971 by its current Executive Chairman, Richard Agree, and its common stock was listed on the New York Stock Exchange in 1994. As of March 31, 2024, the Company owned 2,161 properties, with a total gross leasable area (“GLA”) of approximately 44.9 million square feet.
Issue price:
--